Answers are grounded in this paper and cite their sources.
Many studies have confirmed the activity of thalidomide in MM, as well as an improved response with dexamethasone. Newer thalidomide derivatives with reduced toxicity (neuropathy, teratogenicity) are also promising. Thalidomide with dexamethasone may now represent the treatment of choice for previously untreated patients. Further studies with these and other novel agents early in the course of myeloma may improve complete remission rates and frequency of long-term control.
No takes yet. Share an insight, caveat, or question.
Dimopoulos et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: